Echocardiographic Study of the Haemodynamic Effects of Remifentanil With and Without Glycopyrrolate in Healthy Children
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00315536 |
Recruitment Status :
Completed
First Posted : April 18, 2006
Last Update Posted : January 5, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Urological Surgery | Drug: Administration of remifentanil and glycopyrrolate | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 63 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Echocardiographic Study of the Haemodynamic Effects of Remifentanil With and Without Glycopyrrolate in Healthy Children |
Study Start Date : | May 2006 |
Actual Primary Completion Date : | April 2009 |
Actual Study Completion Date : | April 2009 |

- Drug: Administration of remifentanil and glycopyrrolate
2 mg, intravenius use
- Cardiac index [ Time Frame: Twice in 16 minutes. ]
- Blood pressure [ Time Frame: Twice in 16 minutes. ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Year to 6 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- ASA I and II children
- 1-6 years
- urological surgery
Exclusion Criteria:
- Cardiac disease
- Diabetes

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00315536
Belgium | |
University Hospital Ghent | |
Ghent, Belgium, 9000 |
Principal Investigator: | Koen Reyntjens, MD | University Hospital, Ghent |
Responsible Party: | University Hospital, Ghent |
ClinicalTrials.gov Identifier: | NCT00315536 |
Other Study ID Numbers: |
2006/042 |
First Posted: | April 18, 2006 Key Record Dates |
Last Update Posted: | January 5, 2012 |
Last Verified: | January 2012 |
Glycopyrrolate Remifentanil Analgesics, Opioid Narcotics Central Nervous System Depressants Physiological Effects of Drugs Analgesics Sensory System Agents |
Peripheral Nervous System Agents Adjuvants, Anesthesia Muscarinic Antagonists Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |